[HTML][HTML] Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder and the most common
type of dementia (60–80% of cases). In 2016, nearly 44 million people were affected by AD …
type of dementia (60–80% of cases). In 2016, nearly 44 million people were affected by AD …
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
C Ritchie, AH Noel‐Storr… - Cochrane Database …, 2017 - cochranelibrary.com
Background Research suggests that measurable change in cerebrospinal fluid (CSF)
biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this …
biomarkers occurs years in advance of the onset of clinical symptoms (Beckett 2010). In this …
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage
Three sets of research criteria are available for diagnosis of Alzheimer's disease in subjects
with mild cognitive impairment: the International Working Group-1, International Working …
with mild cognitive impairment: the International Working Group-1, International Working …
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease
AM Fagan, C Xiong, MS Jasielec, RJ Bateman… - Science translational …, 2014 - science.org
Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD)
begins many years before the appearance of cognitive symptoms. Biomarkers are required …
begins many years before the appearance of cognitive symptoms. Biomarkers are required …
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
TT Seppälä, O Nerg, AM Koivisto, J Rummukainen… - Neurology, 2012 - AAN Enterprises
Objective: To assess the relationship between Alzheimer disease (AD)–related pathologic
changes in frontal cortical brain biopsy and AD biomarkers in ventricular vs lumbar CSF, and …
changes in frontal cortical brain biopsy and AD biomarkers in ventricular vs lumbar CSF, and …
A novel matrix-similarity based loss function for joint regression and classification in AD diagnosis
Recent studies on AD/MCI diagnosis have shown that the tasks of identifying brain disease
and predicting clinical scores are highly related to each other. Furthermore, it has been …
and predicting clinical scores are highly related to each other. Furthermore, it has been …
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
IS van Maurik, SJ Vos, I Bos, FH Bouwman… - The Lancet …, 2019 - thelancet.com
Background Biomarker-based risk predictions of dementia in people with mild cognitive
impairment are highly relevant for care planning and to select patients for treatment when …
impairment are highly relevant for care planning and to select patients for treatment when …
Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample
Objective To assess the relationships between fluid and imaging biomarkers of tau
pathology and compare their diagnostic utility in a clinically heterogeneous sample …
pathology and compare their diagnostic utility in a clinically heterogeneous sample …
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease
MR Farlow, N Andreasen, ME Riviere, I Vostiar… - Alzheimer's research & …, 2015 - Springer
Introduction CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses
while avoiding T-cell autoimmune responses. The CAD106 first-in-human study …
while avoiding T-cell autoimmune responses. The CAD106 first-in-human study …
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Alzheimer disease (AD) and Parkinson disease (PD) are the most common
neurodegenerative disorders. For both diseases, early intervention is thought to be essential …
neurodegenerative disorders. For both diseases, early intervention is thought to be essential …